LORAZEPAM TABLETS, USP CIV, 40-8993, Revised – August 2007, Rx only

/LORAZEPAM TABLETS, USP CIV, 40-8993, Revised – August 2007, Rx only
LORAZEPAM TABLETS, USP CIV, 40-8993, Revised – August 2007, Rx only2018-09-06T09:12:40+00:00

Prescription Drug Name:

LORAZEPAM TABLETS, USP CIV, 40-8993, Revised – August 2007, Rx only

ID:

0209bb1e-b8fa-4fa9-a533-4dda028bd369

Code:

34391-3

DESCRIPTION


id: 4ceb02ca-62b1-4029-a5b6-694dd7914075
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2 H-1,4-benzodiazepin-2-one: C15H10Cl2N2O2  MW:321.16 It is a nearly white powder almost insoluble in water. Each lorazepam tablet, to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam. The following inactive ingredients are contained in these products: lactose monohydrate, magnesium stearate, microcrystalline cellulose, polacrilin potassium.

CLINICAL PHARMACOLOGY


id: cd2de036-e9e8-45dc-93ef-567a1e846172
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems. Lorazepam is readily absorbed with an absolute bioavailability of 90 percent. Peak concentrations in plasma occur approximately 2 hours following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. Lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals. The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months. Studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of 1.5 to 3 mg of lorazepam injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age.

INDICATIONS AND USAGE


id: 288f74da-1e4c-4490-8ab6-0279d4a5cb29
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

CONTRAINDICATIONS


id: ce091f99-79ee-4e4a-8faa-d8d532bed861
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Lorazepam is contraindicated in patients with – hypersensitivity to benzodiazepines or to any components of the formulation. – acute narrow-angle glaucoma.

WARNINGS


id: 50669d9e-abf1-44f6-b0ec-2250ccb377f5
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. Lorazepam) is not recommended for use in patients with a primary depressive disorder or psychosis. Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression. (See PRECAUTIONS, Clinically Significant Drug Interactions) Use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence. As with all patients on CNS-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.

PRECAUTIONS


id: 04ef1aac-9bb5-4a9d-88bc-3e1e39401c6f
displayName: PRECAUTIONS SECTION
FDA Article Code: 42232-9

In patients with depression, a possibility for suicide should be borne in mind; benzodiazepines should not be used in such patients without adequate antidepressant therapy. Lorazepam should be used with caution in patients with compromised respiratory function (e.g. COPD, sleep apnea syndrome). Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg. Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued. The usual precautions for treating patients with impaired renal and hepatic function should be observed. As with all benzodiazepines, the use of lorazepam may worsen hepatic encephalopathy; therefore, lorazepam should be used with caution in patients with severe hepatic insufficiency and/or encephalopathy. Dosage for patients with severe hepatic insufficiency should be adjusted carefully according to patient response; lower doses may be sufficient in such patients. In patients where gastrointestinal or cardiovascular disorders coexist with anxiety, it should be noted that lorazepam has not been shown to be of significant benefit in treating the gastrointestinal or cardiovascular component. Esophageal dilation occurred in rats treated with lorazepam for more than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg per day). The effect was reversible only when the treatment was withdrawn within two months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper G.I. disease. Safety and effectiveness of lorazepam in children of less than 12 years has not been established.

ADVERSE REACTIONS


id: 69295c30-280d-4117-be4a-913b7a72a837
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects occurring with high doses. In a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). The incidence of sedation and unsteadiness increased with age. Other adverse reactions to benzodiazepines, including lorazepam are fatigue, drowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, convulsions/seizures tremor, vertigo, eye-function/visual disturbance (including diplopia and blurred vision), dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, coma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactic/oid reactions; dermatological symptoms, allergic skin reactions, alopecia; SIADH, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases in blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam.

OVERDOSAGE


id: 8f7afbe2-3f7c-4745-a10e-96494914098f
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

In postmarketing experience, overdose with lorazepam has occurred predominantly in combination with alcohol and/or other drugs. Therefore, in the management of overdosage , it should be borne in mind that multiple agents may have been taken.

DOSAGE AND ADMINISTRATION


id: 182c64e6-367c-4468-a031-8c5c1b5577f5
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Lorazepam is administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. To facilitate this 0.5 mg, 1 mg, and 2 mg tablets are available. The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day. For anxiety, most patients require an initial dose of 2 to 3 mg/day given b.i.d. or t.i.d. For insomnia due to anxiety or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended to be adjusted as needed and tolerated. The dosage of lorazepam should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicted, the evening dose should be increased before the daytime doses.

HOW SUPPLIED


id: 96341953-793f-46e0-ac22-9331f3856bfc
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

0.5 mg — Each white to off-white, round tablet imprinted with

on one side and 57 on the other side, contains 0.5 mg of Lorazepam, USP. Tablets are supplied in blisters of 30 (NDC 67046-980-30).
1 mg — Each white to off-white, round tablet imprinted with and 59 on one side and bisect on the other side, contains 1 mg of Lorazepam, USP. Tablets are supplied in blisters of 30 (NDC 67046-981-30). 2 mg — Each white to off-white, round tablet imprinted with

and 063 on one side and bisect on the other side, contains 2 mg of Lorazepam, USP. Tablets are supplied in blisters of 30 (NDC 67046-982-30).
Dispense in a tight, light-resistant container as defined in the USP. Store at controlled room temperature 15°-30°C (59°-86°F). Manufactured by:
Actavis Elizabeth LLC
200 Elmora Avenue, Elizabeth, NJ 07207 USA

40-8993

Revised — August 2007 Repackaged by:

Contract Pharmacy Services-PA
125 Titus Ave Suite 200
Warrington, PA 18976 USA Original–3/2011–NJW

PRINCIPAL DISPLAY PANEL


id: b924af49-9d27-4444-82fb-3723497717bc
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

0.5 mg Tablets

PRINCIPAL DISPLAY PANEL


id: d4494b32-d4d0-4720-bf20-4d9edda57ab8
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

1 mg Tablets

PRINCIPAL DISPLAY PANEL


id: fb865224-9056-41ce-984e-7f74f21a4346
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

2 mg Tablets